NextCure, Inc. has presented new preclinical data at the Brittle Bone Society Meeting showing that its novel anti-Siglec-15 antibody, NC605, significantly improves bone microarchitecture and reduces ...

Wif1 overexpression accelerated osteogenic differentiation by activating genes related to late-stage osteogenic differentiation and mitophagy processes. Moreover administering Wif1-overexpressing ...

Schematic diagram illustrating how transplanted young mitochondria activate the AKAP1/cAMP/PKA pathway in aged PDLSCs, restoring mitochondrial membrane potential (ΔΨm), reducing ROS, and enhancing ...

Topline data were announced from two phase 3 studies evaluating setrusumab in patients with osteogenesis imperfecta.

A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...

Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP ...

BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and ...

About the Setrusumab Phase 3 Program Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 ...

Bent bone dysplasia (BBD) is a perinatal-lethal skeletal disorder caused by pathogenic FGFR2 mutations that disrupt bone formation, leading to bent long bones, osteopenia, and craniosynostosis. Bent ...